

Santa Paula Hospital ED / Inpatient

| SPH ED/IP ANTIBIOGRAM 2022 GRAM NEGATIVE % SUSCEPTIBLE (of Isolates tested) | # of isolates tested | Amp/Sulbactam | Cefazolin* | Cefepime | Ceftazidime | Ceftriaxone | Ciprofloxacin | Ertapenem | Gentamicin | Levofloxacin | Meropenem | Nitrofurantoin* | Pip/Tazobactam | Tobramycin | Trimethoprim/Sulfa |
|---|----------------------|---------------|------------|----------|-------------|-------------|---------------|-----------|------------|--------------|-----------|-----------------|----------------|------------|--------------------|
| <i>E. coli</i> | 380 | 58 | 87 | 93 | 91 | 91 | 75 | 100 | 88 | 69 | (100) | 95 | 94 | 88 | 70 |
| <i>Klebsiella aerogenes</i> | 11 | X | 0 | 100 | N | N | 100 | 100 | 100 | 100 | (100) | 9 | 82 | 100 | 100 |
| <i>Klebsiella pneumoniae</i> | 59 | 88 | 93 | 93 | 93 | 93 | 88 | 100 | 97 | 86 | (100) | 15 | 93 | 93 | 90 |
| <i>Proteus mirabilis</i> | 43 | 86 | 91 | 98 | 95 | 95 | 77 | 100 | 95 | 77 | (100) | 0 | 98 | 95 | 88 |
| <i>Pseudomonas aeruginosa</i> | 37 | 0 | 0 | 86 | 92 | 0 | 89 | 0 | 95 | 84 | 94 | 0 | 89 | 97 | 0 |

*Nitrofurantoin and cefazolin: use only for the treatment of uncomplicated cystitis.

Cefazolin results predict results for oral cephalexin and cefuroxime when used to treat uncomplicated cystitis.

X: not tested

N: not recommended

(): presumed susceptibility

9% of *E. coli* are Extended Spectrum Beta Lactamase (ESBL) Producing.

7% of *Klebsiella pneumoniae* are ESBL Producing.

| SPH ED/IP ANTIBIOGRAM 2022 GRAM POSITIVE % SUSCEPTIBLE (of Isolates tested) | # of isolates tested | Amox/Clavulinate | Amp/Sulbactam | Ampicillin | Cefazolin | Cefepime | Ceftriaxone | Ciprofloxacin | Clindamycin | Erythromycin | Levofloxacin | Oxacillin | Penicillin | Tetracycline | Trimethoprim/Sulfa | Vancomycin |
|---|----------------------|------------------|---------------|------------|-----------|----------|-------------|---------------|-------------|--------------|--------------|-----------|------------|--------------|--------------------|------------|
| <i>Staphylococcus aureus</i> (MSSA) | 23 | N | N | 0 | (100) | X | X | N | 91 | N | N | 100 | 0 | 100 | 91 | 100 |
| <i>Staphylococcus aureus</i> (MRSA) | 28 | 0 | 0 | 0 | 0 | 0 | 0 | N | 71 | N | N | 0 | 0 | 93 | 79 | 100 |
| <i>Enterococcus faecalis</i> | 39 | X | X | 100 | 0 | 0 | 0 | N | 0 | 10 | N | X | X | 36 | 0 | 100 |

X: not tested

N: not recommended

(): presumed susceptibility

55% of *Staphylococcus aureus* are Methicillin Resistant (MRSA).

45% of *Staphylococcus aureus* are Methicillin Susceptible (MSSA).

Streptococcus pneumoniae: too few isolates to report.

Data from isolate totals <30 may be statistically unreliable.

VCMC/SPH Antimicrobial Stewardship Committee 3/24/2023.